AIM： To evaluate the long-term outcome and prognostic factors of patients with hilar cholangiocarinoma. METHODS： Ninety-six consecutive patients underwent treatment for malignant hilar bile duct tumors during 1995-2...AIM： To evaluate the long-term outcome and prognostic factors of patients with hilar cholangiocarinoma. METHODS： Ninety-six consecutive patients underwent treatment for malignant hilar bile duct tumors during 1995-2005. Of the 96 patients, 20 were initially treated with surgery （n = 2 R0 / n = 18 R1）. In non-operated patients, data analysis was performed retrospectively. RESULTS： Among the 96 patients, 76 were treated with endoscopic transpapillary （ERC, n = 45） and/or percutaneous transhepatic biliary drainage （PTBD, n = 31）. The mean survival time of these 76 patients undergoing palliative endoscopic and/or percutaneous drainage was 359 ± 296 d. The mean survival time of patients with initial bilirubin levels 〉 10 mg/dL was significantly lower （P 〈 0.001） than patients with bilirubin levels 〈 10 mg/dL. The mean survival time of patients with Bismuth stage Ⅱ （n = 8）, Ⅲ （n = 28） and Ⅳ （n = 40） was 496 =1= 300 d, 441 ± 385 d and 274 ± 218 d, respectively. Thus, patients with advanced Bismuth stage showed a reduced mean survival time, but the difference was not significant. The type of biliary drainage had no significant benefidal effect on the mean survival time （ERC vs PTBD, P = 0.806）. CONCLUSION： Initial bilirubin level is a significant prognostic factor for survival of patients. In contrast, age, tumor stage according to the Bismuth-Corlette classification, and types of intervention are not significant prognostic parameters for survival. Palliative treatment with endoscopic or percutaneous biliary drainage is still suboptimal, new diagnostic and therapeutic tools need to be evaluated.展开更多
Non-specific abdominal complaints are a considerable problem worldwide. Many patients are affected and many differential diagnoses have to be considered. Among these, carbohydrate malabsorption seems to play an import...Non-specific abdominal complaints are a considerable problem worldwide. Many patients are affected and many differential diagnoses have to be considered. Among these, carbohydrate malabsorption seems to play an important role. However, so far, only incomplete absorption of lactose is broadly accepted, while the malabsorption of fructose and sorbitol is still underestimated, although in many parts of the world it is much more frequent. Despite the success of dietary interventions in many patients, there are still a lot of unanswered questions that make further investigations展开更多
AIM:This study analyzed clinical long-term outcomes after endoscopic therapy,including the incidence and treatment of relapse. METHODS:This study included 19 consecutive patients(12 male,7 female,median age 54 years)w...AIM:This study analyzed clinical long-term outcomes after endoscopic therapy,including the incidence and treatment of relapse. METHODS:This study included 19 consecutive patients(12 male,7 female,median age 54 years)with obstructive chronic pancreatitis who were admitted to the 2nd Medical Department of the Technical University of Munich.All patients presented severe chronic pancreatitis(stageⅢ°)according to the Cambridge classification.The majority of the patients suffered intermittent pain attacks.6 of 19 patients had strictures of the pancreatic duct;13 of 19 patients had strictures and stones.The first endoscopic retrograde pancreatography(ERP)included an endoscopic sphincterotomy, dilatation of the pancreatic duct,and stent placement.The first control ERP was performed 4 wk after the initial intervention,and the subsequent control ERP was performed after 3 mo to re-evaluate the clinical and morphological conditions.Clinical follow-up was performed annually to document the course of pain and the management of relapse.The course of pain was assessed by a pain scale from 0 to 10.The date and choice of the therapeutic procedure were documented in case of relapse. RESULTS:Initial endoscopic intervention was successfully completed in 17 of 19 patients.All 17 patients reported partial or complete pain relief after endoscopic intervention.Endoscopic therapy failed in 2 patients. Both patients were excluded from further analysis.One failed patient underwent surgery,and the other patient was treated conservatively with pain medication.Seventeen of 19 patients were followed after the successful completion of endoscopic stent therapy.Three of 17 patients were lost to follow-up.One patient was not avail-able for interviews after the 1st year of follow-up.Two patients died during the 3rd year of follow-up.In both patients chronic pancreatitis was excluded as the cause of death.One patient died of myocardial infarction, and one patient succumbed to pneumonia.All three patients were excluded from follow-up analysis.Followup was successfully completed in 14 of 17 patients.4 patients at time point 3,2 patients at time point 4,3 patients at time point 5 and 2 patients at time point 6 and time point 7 used continuous pain medication after endoscopic therapy.No relapse occurred in 57%(8/14) of patients.All 8 patients exhibited significantly reduced or no pain complaints during the 5-year follow-up.Seven of 8 patients were completely pain free 5 years after endoscopic therapy.Only 1 patient reported continuous moderate pain.In contrast,7 relapses occurred in 6 of the 14 patients.Two relapses were observed during the 1st year,2 relapses occurred during the 2nd year,one relapse was observed during the 3rd year,one relapse occurred during the 4th year,and one relapse occurred during the 5th follow-up year.Four of these six patients received conservative treatment with endoscopic therapy or analgesics.Relapse was conservatively treated using repeated stent therapy in 2 patients.Analgesic treatment was successful in the other 2 patients. CONCLUSION:57%of patients exhibited long-term benefits after endoscopic therapy.Therefore,endoscopic therapy should be the treatment of choice in patients being inoperable or refusing surgical treatment.展开更多
文摘AIM： To evaluate the long-term outcome and prognostic factors of patients with hilar cholangiocarinoma. METHODS： Ninety-six consecutive patients underwent treatment for malignant hilar bile duct tumors during 1995-2005. Of the 96 patients, 20 were initially treated with surgery （n = 2 R0 / n = 18 R1）. In non-operated patients, data analysis was performed retrospectively. RESULTS： Among the 96 patients, 76 were treated with endoscopic transpapillary （ERC, n = 45） and/or percutaneous transhepatic biliary drainage （PTBD, n = 31）. The mean survival time of these 76 patients undergoing palliative endoscopic and/or percutaneous drainage was 359 ± 296 d. The mean survival time of patients with initial bilirubin levels 〉 10 mg/dL was significantly lower （P 〈 0.001） than patients with bilirubin levels 〈 10 mg/dL. The mean survival time of patients with Bismuth stage Ⅱ （n = 8）, Ⅲ （n = 28） and Ⅳ （n = 40） was 496 =1= 300 d, 441 ± 385 d and 274 ± 218 d, respectively. Thus, patients with advanced Bismuth stage showed a reduced mean survival time, but the difference was not significant. The type of biliary drainage had no significant benefidal effect on the mean survival time （ERC vs PTBD, P = 0.806）. CONCLUSION： Initial bilirubin level is a significant prognostic factor for survival of patients. In contrast, age, tumor stage according to the Bismuth-Corlette classification, and types of intervention are not significant prognostic parameters for survival. Palliative treatment with endoscopic or percutaneous biliary drainage is still suboptimal, new diagnostic and therapeutic tools need to be evaluated.
文摘Non-specific abdominal complaints are a considerable problem worldwide. Many patients are affected and many differential diagnoses have to be considered. Among these, carbohydrate malabsorption seems to play an important role. However, so far, only incomplete absorption of lactose is broadly accepted, while the malabsorption of fructose and sorbitol is still underestimated, although in many parts of the world it is much more frequent. Despite the success of dietary interventions in many patients, there are still a lot of unanswered questions that make further investigations
文摘AIM:This study analyzed clinical long-term outcomes after endoscopic therapy,including the incidence and treatment of relapse. METHODS:This study included 19 consecutive patients(12 male,7 female,median age 54 years)with obstructive chronic pancreatitis who were admitted to the 2nd Medical Department of the Technical University of Munich.All patients presented severe chronic pancreatitis(stageⅢ°)according to the Cambridge classification.The majority of the patients suffered intermittent pain attacks.6 of 19 patients had strictures of the pancreatic duct;13 of 19 patients had strictures and stones.The first endoscopic retrograde pancreatography(ERP)included an endoscopic sphincterotomy, dilatation of the pancreatic duct,and stent placement.The first control ERP was performed 4 wk after the initial intervention,and the subsequent control ERP was performed after 3 mo to re-evaluate the clinical and morphological conditions.Clinical follow-up was performed annually to document the course of pain and the management of relapse.The course of pain was assessed by a pain scale from 0 to 10.The date and choice of the therapeutic procedure were documented in case of relapse. RESULTS:Initial endoscopic intervention was successfully completed in 17 of 19 patients.All 17 patients reported partial or complete pain relief after endoscopic intervention.Endoscopic therapy failed in 2 patients. Both patients were excluded from further analysis.One failed patient underwent surgery,and the other patient was treated conservatively with pain medication.Seventeen of 19 patients were followed after the successful completion of endoscopic stent therapy.Three of 17 patients were lost to follow-up.One patient was not avail-able for interviews after the 1st year of follow-up.Two patients died during the 3rd year of follow-up.In both patients chronic pancreatitis was excluded as the cause of death.One patient died of myocardial infarction, and one patient succumbed to pneumonia.All three patients were excluded from follow-up analysis.Followup was successfully completed in 14 of 17 patients.4 patients at time point 3,2 patients at time point 4,3 patients at time point 5 and 2 patients at time point 6 and time point 7 used continuous pain medication after endoscopic therapy.No relapse occurred in 57%(8/14) of patients.All 8 patients exhibited significantly reduced or no pain complaints during the 5-year follow-up.Seven of 8 patients were completely pain free 5 years after endoscopic therapy.Only 1 patient reported continuous moderate pain.In contrast,7 relapses occurred in 6 of the 14 patients.Two relapses were observed during the 1st year,2 relapses occurred during the 2nd year,one relapse was observed during the 3rd year,one relapse occurred during the 4th year,and one relapse occurred during the 5th follow-up year.Four of these six patients received conservative treatment with endoscopic therapy or analgesics.Relapse was conservatively treated using repeated stent therapy in 2 patients.Analgesic treatment was successful in the other 2 patients. CONCLUSION:57%of patients exhibited long-term benefits after endoscopic therapy.Therefore,endoscopic therapy should be the treatment of choice in patients being inoperable or refusing surgical treatment.
